HAGE has been found to be induced in a dose dependent manner by 5-aza-2′-deoxycytidine [54], a treatment now being used in Phase II clinical trials to overcome T cell exhaustion that is caused by AML blast arginase II activity [48]. Here, DDX43 is linked to acute myeloid leukemia.